Icon and PRA announce CRO mega-deal

Dublin-based Icon, a contract research and drug development company, has announced that it is acquiring one of its competitors, PRA Health Services.
Feb. 25, 2021

Dublin-based Icon, a contract research and drug development company, has announced that it is acquiring one of its competitors, PRA Health Services. The deal is valued at about $12 billion.

After suffering a 2020 revenue slump brought on by clinical trial disruptions related to the COVID-19 pandemic, Icon’s match-up with PRA will help create a mega-CRO with strategic partnerships already developed with dozens of major players in pharma. And once complete, Icon says the merger will give rise to a healthcare intelligence/CRO company that will hold a top spot in several key market segments.

Because PRA has invested in digital platforms — such as remote monitoring — Icon’s acquisition of the company will allow it to expand its tech know-how for clinical trials. The deal will also help Icon broaden its reach in Asian countries such as China.

Read the full Wall Street Journal report.

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates